Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to determine if chronic pain subjects on around-the-clock
opioids who are receiving 100 to 220 mg oral morphine sulfate equivalent (MSE) can be safely
transitioned on to buprenorphine hydrochloride (HCl) buccal film at 50% of their MSE dose
without inducing opioid withdrawal or reversing analgesic effects.
Phase:
Phase 2
Details
Lead Sponsor:
BioDelivery Sciences International Endo Pharmaceuticals